(Reuters) - Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. Shares of the specialty pharmaceutical company rose 10.5 percent before the bell. The study was testing the drug, BIOD-531, against Eli Lilly and Co's Humalog Mix 75/25 in type 2 diabetes patients with moderate insulin resistance who use 50-200 units of insulin daily. In type 2 diabetes, the most common form of the disease, the body does not use insulin properly, leading to high levels of blood sugar. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment